By Bio-IT World Staff
August 12, 2013 | GenoSpace, PathGroup and Thomson Reuters have launched an initiative to develop and deliver a best-in-class personalized medicine service for oncology.
The partnership integrates PathGroup’s SmartGenomics sequencing and array services with Thomson Reuters’ information on genes, variants and therapeutic implications. These are then overlaid with GenoSpace’s advanced analytical and information integration capabilities. Oncologists will soon start receiving individualized reports that provide targeted information to help identify the best possible therapy for their patients.
“Collaboration is essential to deliver more precise medical solutions in today’s Big Data environment,” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences in a statement. “Our coalition with GenoSpace and PathGroup leverages each organization’s unique assets, making significant improvements in treatment options for cancer patients.”
PathGroup’s industry-leading anatomic, clinical and molecular pathology services are integrated with the unparalleled information on genes, variants and therapeutic implications from Thomson Reuters. These are then overlaid with GenoSpace’s advanced analytical and information integration capabilities to place this diverse data into context. Oncologists will soon start receiving individualized reports that provide targeted information to help identify the best possible therapy for their patients.
“We have entered a new age of personalized medicine,” said Ben Davis, MD, Chairman, President and CEO of PathGroup. “It is one in which the unique genetic profile of each patient’s tumor, placed in the context of their disease, can help physicians select treatment options and improve outcomes. The GenoSpace and Thomson Reuters contributions to our SmartGenomics analyses add a highly sophisticated tool to our pathologist’s armamentarium in developing a patient genomic dossier.”
“One challenge in personalized medicine is assuring that what the physicians see is the most accurate and up-to-date information,” added Joseph Donahue, senior vice president of Thomson Reuters Life Sciences. “Thomson Reuters has always been focused on providing the most comprehensive information on genes and their functions, and we are delighted to be able to partner with PathGroup and GenoSpace to demonstrate how that information can be used to improve health care delivery.”
John Quackenbush, Ph.D., CEO of GenoSpace, said, “The GenoSpace FullView™ and GenoSpace for Clinical™ platforms integrate the vast pathology resources available at PathGroup with sequence and array data and information, tying in the extensive knowledgebase available through Thomson Reuters, and deliver concise, relevant and actionable reports to oncologists in a format that they find useful in making treatment decisions. By bringing together the complementary strengths of each company, we will be able to deliver a market-leading solution in personalized genomic medicine.”